HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
2,6-dihydroxy-3-cyanopyridine
inhibitor of 5-fluorouracil degradation
Also Known As:
2,6-CNDP; 3-cyano-2,6-dihydroxypyridine
Networked:
3
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridines: 88
2,6-dihydroxy-3-cyanopyridine: 3
Related Diseases
1.
Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/1994 - "
Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation, was administered to 71 non-small cell lung cancer (NSCLC) patients in a multi-center phase II study.
"
2.
Yoshida Sarcoma
06/01/1989 - "
These methods were additional infusion of 5-FU for a short period (4 h) or oral administration of UFT or Tegafur during long-term CVI of 5-FU that alone gave a plasma 5-FU level of about 50 ng/ml. The antitumor effect on Yoshida sarcoma was markedly potentiated when an additive dose of 5-FU combined with 3-cyano-2,6-dihydroxypyridine (CNDP), a potent inhibitor of 5-FU degradation, giving a plasma level of about 500 ng/ml, was infused for 4 h.
"
3.
Lung Neoplasms (Lung Cancer)
01/01/1994 - "
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
"
Related Drugs and Biologics
1.
Fluorouracil (Carac)
2.
Emitefur
3.
Tegafur
Related Therapies and Procedures
1.
Oral Administration